3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
159 citations
,
August 2010 in “British journal of dermatology/British journal of dermatology, Supplement” Hydroxychloroquine effectively reduces symptoms of frontal fibrosing alopecia, especially in the first 6 months.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” Six African American women experienced hair loss after switching to a new HIV medication.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
4 citations
,
September 2013 in “Journal of biomolecular structure and dynamics/Journal of biomolecular structure & dynamics” Caribine from traditional Chinese medicine may help treat hair loss.
March 2025 in “International Journal of Dermatology” Baricitinib may help people with long-term alopecia areata.
23 citations
,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
46 citations
,
January 2000 in “The Journal of Clinical Endocrinology and Metabolism”
July 2020 in “CRS 2020 Virtual Annual Meeting” Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity”
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
13 citations
,
March 2020 in “Genes” Disrupting the FGF5 gene in rabbits leads to longer hair by extending the hair growth phase.
6 citations
,
January 2017 in “British Journal of Dermatology” Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting older women, with no known cause and treatments that may help stabilize hair loss.
7 citations
,
September 2015 in “Actas Dermo-Sifiliográficas” Hair transplantation for Frontal Fibrosing Alopecia may work if done after the disease is inactive for 2 years and with ongoing treatment after surgery.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
13 citations
,
December 2007 in “The Journal of Dermatology” Fexofenadine may help treat alopecia areata.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
March 2005 in “Journal of the American Academy of Dermatology” Cosmetic treatments can replenish key amino acids in damaged hair, improving its strength and appearance.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
March 2018 in “Dermatología Argentina” The study found that the average age of women diagnosed with Frontal Fibrosing Alopecia in Argentina is higher than in other countries, but their symptoms are similar.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.